<DOC>
	<DOC>NCT01621178</DOC>
	<brief_summary>The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.</brief_summary>
	<brief_title>A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Men and nonpregnant women aged ≥18 years Hemoglobin A1c (HbA1c) ≥7.5% and ≤10.5% Type 2 diabetes on insulin or insulin + oral antihyperglycemic medication Participants with presumed diabetic kidney disease with or without hypertensive nephrosclerosis diagnosed with moderate or severe CKD with estimated glomerular filtration rate (eGFR) of ≥15 to &lt;60 milliliters per minute (mL/min)/1.73 meter squared (m^2) Able and willing to perform multiple daily injections Body mass index (BMI) between 23 and 45 kilogram/square meter (kg/m^2) Stage 5 CKD as defined by eGFR &lt;15 mL/min/1.73 m^2 OR having required dialysis Rapidly progressing renal dysfunction likely to require renal replacement History of a transplanted organ Type 1 diabetes mellitus At screening a systolic blood pressure of ≥150 mmHg or a diastolic blood pressure of ≥90 mmHg with or without antihypertensive medication An episode of ketoacidosis or hyperosmolar state/coma in the past 6 months or a history of severe hypoglycemia in the past 3 months prior to the Screening Visit Cardiovascular conditions within 12 weeks prior to randomization: acute myocardial infarction, New York Heart Association (NYHA) class III or class IV heart failure, or cerebrovascular accident (stroke) Acute or chronic hepatitis Signs and symptoms of chronic or acute pancreatitis, or were in the past diagnosed with pancreatitis Serum calcitonin ≥35 picograms per milliliter (pg/mL) at Screening Visit Self or family history of medullary Ccell hyperplasia, focal hyperplasia, or carcinoma Known history of untreated proliferative retinopathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>